Industry leaders outlined practical paths to scale autologous and allogeneic cell therapies by combining automation, closed‑system manufacturing and global networks. Cellares executives described how automation and modular facilities can reduce manual variation and bottlenecks, while a multidisciplinary industry panel detailed regulatory, quality and supply‑chain hurdles that must be addressed for commercial rollout. Speakers emphasized that autologous therapies—made from a patient’s own cells—require coordinated logistics, robust quality systems and regulatory alignment to be commercially viable. The conversation highlighted near‑term investments in process standardization, workforce training and facility design as priorities to make cell therapies more accessible.